VSTM2L

Across TCGA pan-cancer cohorts, VSTM2L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of VSTM2L’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where VSTM2L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types VSTM2L is over-expressed in tumor.

LUAD, PDAC, and LSCC are the cancer types where VSTM2L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VSTM2L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	+1.355	<.001	8	view →
PDAC	Male	All	+1.680	.001	3	view →
LSCC	Male	All	+0.624	.010	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

VSTM2L–LUAD

Open the LUAD breakdown →